Clinical Data Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial PharmaTimesResponders achieved weight loss and improvements in physical functionMetabolic & GLP-1Read full story pharminent May 13, 2026 (Last updated: May 21, 2026) PharmaTimes Responders achieved weight loss and improvements in physical function Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: UAE approves AstraZeneca’s Baxfendy for hypertensionNext: Clock starts ticking on UK’s single patient record plan Related Stories Clinical Data ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma pharminent June 2, 2026 Clinical Data ASCO26: In vivo oncology approaches continue to show promise pharminent June 2, 2026 Clinical Data ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come pharminent June 2, 2026
